Fig. 2: Selected ionizable lipids under clinical development for COVID-19 mRNA vaccines and other RNA therapeutics. | Nature Communications

Fig. 2: Selected ionizable lipids under clinical development for COVID-19 mRNA vaccines and other RNA therapeutics.

From: An ionizable lipid toolbox for RNA delivery

Fig. 2: Selected ionizable lipids under clinical development for COVID-19 mRNA vaccines and other RNA therapeutics.The alternative text for this image may have been generated using AI.

Ionizable lipids used in on-going clinical trials have not been publicly disclosed, so one of the possible structures (Acuitas A946, Arcturus Lipid 2,2 (8,8) 4C CH347, Genevant CL148 and LP0149,50) is shown, respectively. i.v. intravenous, i.m. intramuscular.

Back to article page